Can your AI stand up to the FDA’s new 7-step credibility framework? Ours can. 🚀. We just published a whitepaper that shows how we’re using #AI to boost trial power—without changing the design or adding participants. If you're serious about credible, trial-ready AI, this is worth

👥 “By incorporating digital twins into the analysis, sponsors can maximize the available power of their study. That power can then be used in different ways: to increase confidence in the trial’s results or to reduce the number of participants needed – especially in the control.

The FDA’s 7-step framework for AI is clear. So is our alignment with it. 🚀 . Read our whitepaper to learn how we boost trial power without increasing sample sizes:

🔮 What if you could see into the future of every patient in your trial? At the 2025 “Digital Breakthrough for Pharma” Summit hosted by @bmsnews, Unlearn’s co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

AI in trials is moving fast. Learn how we’re staying in step with the FDA in our latest blog. 🚀

#UnlearnerSpotlight 🚀 “It's exciting and rewarding to get to work closely with a remarkably smart, diverse and committed group of people on a shared mission to change not just the clinical research industry, but also patients' lives.”

“We’re not just tweaking the system,” @AnotherJonWalsh, co-founder and Chief Scientific Officer at Unlearn, explained during a discussion hosted by @pymnts CEO Karen Webster. “We’re re-architecting it.” 🚀

RT @pymnts: 🧬 What are digital twins? AI models that predict how patients would respond to placebos, without giving them one. This means mo….

🧪 The FDA’s new framework is transforming how #AI is integrated into #clinicaltrials, driving a rapid evolution in #drugdevelopment. If you're attending @DrugInfoAssn 2025, don't miss our co-founder and Machine Learning Scientist Aaron Smith's presentation, “Technical and

👥 "Digital twins ultimately provide answers to counterfactual questions about an individual—How will their disease progress? What will likely be effects of interventions? What are the risk of significant health events?” — Aaron Smith, Unlearn co-founder and Machine Learning.

The @FDA wants #AI in trials to follow a 7-step credibility framework. This whitepaper shows how we do exactly that to boost trial power without requiring additional participants. 📄 Read more:

Building on our dedication to advancing #ALS research, we were proud to contribute to the progress showcased at #ENCALS2025 through our poster presentation, “Enhancing Prognostic Value of Plasma NfL for Amyotrophic Lateral Sclerosis (ALS) Through Digital Twins to Improve Trial

The @FDA has launched its new generative #AI tool, Elsa, to help optimize workflows across the agency. Hear from our co-founder & Chief Scientific Officer, @AnotherJonWalsh, on the implications for #drugdevelopment: 💊

“We’re at an inflection point. Digital twins are no longer theoretical. They’re working, they’re trusted, and they’re delivering value today.” — Aaron Smith in the @Forbes article, "The Future Of Drug Trials Might Be Virtual AI Patients" by @torcon 🚀

🧠 Did you know 500,000 new cases of Alzheimer's disease are diagnosed each year? June is Alzheimer’s and Brain Awareness Month, a time to bring visibility and drive action towards curing this debilitating disease. We’re proud to be a part of the fight, using #digitaltwins to

🎉 We’re excited to join @bmsnews’s exclusive event, 'Digital Breakthrough for Pharma Summit 2025' on June 3! Our co-founder and Machine Learning Scientist, Aaron Smith, will be a featured speaker, presenting “AI-Powered Digital Twins: Practical Applications in Clinical

Attending #ENCALS2025? Don’t miss our poster presentation, “Enhancing Prognostic Value of Plasma NfL for Amyotrophic Lateral Sclerosis (ALS) Through Digital Twins to Improve Trial Efficiency.” . 🗓 Thursday, June 5 | 🕒 4:30–5:30 PM | 📍 Poster Session B. Connect with our team to

#UnlearnerSpotlight 🚀 “It’s incredibly meaningful to be part of a team working toward something bigger than ourselves—improving clinical trials to help real people. On top of that, I’m constantly inspired by the brilliant minds around me."

Building on our commitment to advancing #ALS research, we’re proud to continue driving progress at #ENCALS2025. Join us for our poster presentation, “Enhancing Prognostic Value of Plasma NfL for Amyotrophic Lateral Sclerosis (ALS) Through Digital Twins to Improve Trial

🧠 Early #ALS trials present significant challenges, with limited patient populations and no validated biomarkers, complicating the assessment of drug efficacy. At the ALS Drug Development Summit, we co-presented alongside @ProJenX, highlighting how Unlearn’s ALS DTG model has.